Last reviewed · How we verify
sofosbuvir and daclatasvir — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
sofosbuvir and daclatasvir (sofosbuvir and daclatasvir) — Tehran University of Medical Sciences.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| sofosbuvir and daclatasvir TARGET | sofosbuvir and daclatasvir | Tehran University of Medical Sciences | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- sofosbuvir and daclatasvir CI watch — RSS
- sofosbuvir and daclatasvir CI watch — Atom
- sofosbuvir and daclatasvir CI watch — JSON
- sofosbuvir and daclatasvir alone — RSS
Cite this brief
Drug Landscape (2026). sofosbuvir and daclatasvir — Competitive Intelligence Brief. https://druglandscape.com/ci/sofosbuvir-and-daclatasvir. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing